Fresenius biopharma business hits 2030 EBIT margin target of 20% early, ahead of analyst expectations

Fresenius's biopharma business has achieved its 2030 adjusted EBIT margin target of 20% earlier than anticipated, with analysts having expected the milestone between 2027 and 2028. Growth prospects follow a recent deal with WuXi Biologics.

Detected & updated continuously · Source: Nebula